Areas of Focus


Since the discovery of penicillin in 1928, antibiotics have saved countless lives. However, as Alexander Fleming warned during a lecture in 1945, the misuse and overuse of antibiotics have led to the development of bacteria that are resistant to one or more classes of antibiotics. Global organizations including the Infectious Disease Society of America, Health Canada, the UK Department of Health and the UN General Assembly concur that the development of new antibiotics is a crucial element in the effort to address the serious and growing threat of antibiotic resistance.


Aniko is committed to applying the company’s 30-years of cumulative experience in anti-infectives research to the development of novel antibiotics targeting Gram-negative and Gram-positive microbes. Among those areas of interest are the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), which the World Health Organization has identified as the most critical unmet needs. 


Discovery and Research Programs 


Aniko Pharmaceuticals acquired rights in 2012 to a family of beta‑lactamase inhibitors that were shown to have activity against pathogens containing all four classes of β‑lactamases: Class A (including ESBL and KPC), Class B (including NDM-1), Class C (chromosomally encoded Gram-negative enzymes) and a portion of Class D (oxacillin hydrolysing). When used in combination with beta‑lactam antibiotics (eg: penicillin, cephalosporins, monobactams and carbapenems), beta‑lactamase inhibitors have the potential to restore the antibiotic’s potency against bacterial infections currently resistant to therapy.


After conducting optimization and pre-clinical research, this family of compounds was licensed in 2015 to Roche in a deal valued at up to $750 million in upfront and milestone payments and royalties.


Currently, Aniko is pursuing several discovery programs, each of which may yield one or more novel antibiotics candidates. The company is evaluating the antibiotic properties of these potential candidates, and expects to select one or more for formal preclinical development in 2017.